	#2				
	14 Parid DATIBITA CED O E ANN				
قال	11 Rec'd PCT/PTO SEP 2 5 2001				
FORM PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY 'S DOCKET NUMBER				
(REV. 11-2000)	15280-3862US				
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)				
CONCERNING A FILING UNDER 35 U.S.C. 371	09/869,003				
INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED				
PCT/US00/00372 07 January 2000	11 January 1999				
TITLE OF INVENTION NOVEL HIV RELATED PEPTIDES					
THE OF INVENTION NOVEL HIV RELATED LET HDES					
APPLICANT(S) FOR DO/EO/US SCALA, Giuseppe; CHEN, Xueni; COHEN	I. Oren, J.: FAUCI, Anthony, S.				
ATTENNICOTOR DOLLO CO DOLLO, GLASOPPO, CILDA, TAGAM, COLLO	, 51611, 01, 1110 61, 111111611, 51				
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:				
1. This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.					
2. A This is a SECOND or SUBSEQUENT submission of items concerning a filing					
3. This is an express request to begin national examination procedures (35 U.S.C. 3	71(f). The submission must include items				
 (5), (6), (9) and (21) indicated below. 4. The US has been elected by the expiration of 19 months from the priority date (A) 	Article 31).				
5. A copy of the International Application as filed (35 U.S.C. 37(c)(2))					
a. is attached hereto (required only if not communicated by the Internation	al Bureau).				
b. has been communicated by the International Bureau					
c. is not required, as the application was filed in the United States Receiving					
6. An English language translation of the International Application as filed (35 U.S	.C. 371(c)(2)).				
a. is attached hereto.					
b. has been previously submitted under 35 U.S.C. 154(d)(4).					
7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)). a. are attached hereto (required only if not communicated by the International Bureau).					
 a. are attached hereto (required only it not communicated by the Internation b. have been communicated by the International Bureau. 	Mai Dai vaa)i				
b. have been communicated by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired.					
d. have not been made and will not be made.					
8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).					
9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). (5 counterpart declarations)					
10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).					
Items 11 to 20 below concern document(s) or information included:					
11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.					
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.					
13. A FIRST preliminary amendment.					
14. A SECOND or SUBSEQUENT preliminary amendment.					
15. A substitute specification. 16. A change of power of attorney and/or address letter.					
17. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 – 1.825.					
18. A second copy of the published international application under 36 U.S.C.					
19. A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).					
20. Other items or information:					
copy of Notification of Missing Requirements					
Communication under 37 C.F.R. 1.821-1.825					
copy of Notificatino to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid					
Sequence Disclosures					

1/S/ Application no. (if known 09/869,003	,	INTERNATIONAL APPLICATION NO. PCT/US00/00372		ATTORNEY'S DOCKET NUMBER 15280-3862US		
			CALCULATIONS PTO USE ONLY			
BASIC NATIONAL FEE (37 CFR 1.492(A) (1) – (5)):						
Neither international preliminary examination fee (37 CFR 1.492) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO\$1000.00						
International preliminary examination fee (37 CFR 1.482) paid to USPTO but International Search report prepared by the EPO of JPO\$860.00						
International preliminary examination fee (37 CFR 1.482) paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO\$710.00						
International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)						
International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)(4)\$100.00						
	TER APPROPRIATE BAS		XI 30	\$		
Surcharge of \$130.00 for furnishing the oath or declaration later than 20 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$130.00		
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$		
Total claims	- 20 = - 3 =		x \$18.00 x \$80.00	\$ \$	 	
Independent claims MULTIPLE DEPEND		ble)	+ 270.00	\$	1	
MOETH EE DETEND	MULTIPLE DEPENDENT CLAIM(S) (if applicable) + 270.00 TOTAL OF ABOVE CALCULATIONS =			\$130.00		
				\$		
		SUI	BTOTAL =	\$130.00		
Processing fee of \$130.00 for furnishing the English translation later than 20 30 months from the earliest claimed priority date (37 CFT 1.492(f).		\$				
TOTAL NATIONAL FEE =			\$130.00			
Fee for recording the enclosed assignment (37 CFR 1.2(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +			\$			
TOTAL FEES ENCLOSED =			\$130.00			
				Amount to be	\$	
<u>.</u>				refunded: charged:	•	
 a. A check in the amount of \$ to cover the above fees is enclosed. b. Please charge my Deposit Account No. 20-1430 in the amount of \$130.00 to cover the above fees. 						
overpayme	nissioner is hereby authorized ant to Deposit Account No. 2	0-1430. A duplicate copy of	f this sheet is en	closed.	_	
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.						
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b) must be filed and granted to restore the application to pending status.						
SEND ALL CORRES	PONDENCE TO:			_ SIGNATURE	1 Jell	
Jean M. Lockyer				1)	7	
Townsend and Tow	nsend and Crew LLP			V		
Two Embarcadero (Center, 8th Floor					
San Francisco, CA	•			Jean M. Lockye NAME	<u>r</u>	
				44,879 REGISTRATION N	UMBER	

EXPRESS MAIL NO.: EL827153214US

DATE OF DEPOSIT: September 25, 2001

Attorney Docket No.: 15280-3862US

Enclosures:

Form PTO 1390
4 counterpart Declarations
copy of Notification of Missing Requirements
Communication under 37 C.F.R. 1.821-1.825 and Preliminary
Amendment
copy of Notification to Comply with Requirements for Patent
Applications Containing Nucleotide Sequence and/or
Amino Acid Sequence Disclosures

SF 1193773 v1